Tech Company Financing Transactions
ABK Biomedical Funding Round
On 4/10/2019, ABK Biomedical raised $30 million in Series B funding from F-Prime Capital, Varian Medical Systems and private investors.
Transaction Overview
Company Name
Announced On
4/10/2019
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
F-Prime Capital (Lead Investor) (Ketan Patel)
Varian Medical Systems (Lead Investor) (Gregory Sorensen)
Proceeds Purpose
ABK Biomedical will use the funding for continued focused product development of its Eye90 microspheres, which are designed for transarterial radiation therapy for liver tumors, and its Easi-Vue microspheres for bland embolic treatment of hypervascular tumors.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
155 Chain Lake Dr. 32
Halifax NS, B3S 1B3
Canada
Halifax NS, B3S 1B3
Canada
Phone
Website
Email Address
Overview
ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Mangano
Chief Financial Officer
Michael Tyson
Chief Medical Officer
Robert Abraham
VP - Bus. Development
Gary Donofrio
VP - Operations
Marc Gregoire
VP - Regulatory Affairs
David Dobrowski
Browse more venture capital transactions:
Prev: 4/10/2019: Buckzy Payments venture capital transaction
Next: 4/10/2019: UserIQ venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs